E-submission
Search
- Page Path
- HOME > Search
Original Articles
- Mesenchymal Stromal Cells Promote Tumor Progression in Fibrosarcoma and Gastric Cancer Cells
- Byunghoo Song, Bokyung Kim, Se-Ha Choi, Kyo Young Song, Yang-Guk Chung, Youn-Soo Lee, Gyeongsin Park
- Korean J Pathol. 2014;48(3):217-224. Published online June 26, 2014
- DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.3.217
- 7,551 View
- 51 Download
- 8 Crossref
-
Abstract
PDF Background Extensive evidence has accumulated regarding the role of mesenchymal stromal cells (MSCs) in tumor progression, but the exact effects and mechanisms underlying this role remain unclear. We investigated the effects of MSC-associated tumor progression in MSC-sarcoma models and a gastric cancer metastatic model.
Methods We conducted an
in vitro growth kinetics assay and anin vivo tumor progression assay for sarcoma cells and gastric cancer cells in the presence or absence of MSCs.Results MSC-cocultured human fibrosarcoma cells (HT1080) showed accelerated growth compared with HT1080 alone (79- vs 37-fold change, p<.050). For HT1080, human MSC-coinjected tumors showed significantly greater and highly infiltrative growth compared to those of HT1080 alone (p=.035). For mouse fibrosarcoma cells (WEHI164), mouse MSC-coinjected tumors had greater volume than those of WEHI164 alone (p=.141). For rat sarcoma cells (RR1022), rat MSC-coinjected tumors exhibited greater volume and infiltrative growth than those of RR1022 alone (p=.050). For human gastric cancer cells (5FU), tumors of 5FU alone were compact, nodular in shape, and expansile with good demarcation and no definite lung metastatic nodules, whereas tumors grown in the presence of human MSCs showed highly desmoplastic and infiltrative growth and multiple lung metastasis.
Conclusions We observed morphological evidence for MSC-associated tumor progression of fibrosarcomas and gastric cancer cells.
-
Citations
Citations to this article as recorded by
- Transition between canonical to non-canonical Wnt signaling during interactions between mesenchymal stem cells and osteosarcomas
Asulin Masha, Ghedalia-Peled Noa Ben, Erez Ifat Cohen, Ventura Yvonne, Vago Razi
Open Journal of Orthopedics and Rheumatology.2020; : 037. CrossRef - Mesenchymal stem-cell therapy for perianal fistulas in Crohn’s disease: a systematic review and meta-analysis
F. Cheng, Z. Huang, Z. Li
Techniques in Coloproctology.2019; 23(7): 613. CrossRef - Human mesenchymal stromal cells do not promote recurrence of soft tissue sarcomas in mouse xenografts after radiation and surgery
PAOLA A. FILOMENO, KYUNG-PHIL KIM, NARA YOON, IRAN RASHEDI, VICTOR DAYAN, RITA A. KANDEL, XING-HUA WANG, TANIA C. FELIZARDO, ELLIOT BERINSTEIN, SALOMEH JELVEH, ANDREA FILOMENO, JEFFREY A. MEDIN, PETER C. FERGUSON, ARMAND KEATING
Cytotherapy.2018; 20(8): 1001. CrossRef - Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases
C. Grégoire, C. Lechanteur, A. Briquet, É. Baudoux, F. Baron, E. Louis, Y. Beguin
Alimentary Pharmacology & Therapeutics.2017; 45(2): 205. CrossRef - Effect of hGC-MSCs from human gastric cancer tissue on cell proliferation, invasion and epithelial-mesenchymal transition in tumor tissue of gastric cancer tumor-bearing mice
Lin Song, Xin Zhou, Hong-Jun Jia, Mei Du, Jin-Ling Zhang, Liang Li
Asian Pacific Journal of Tropical Medicine.2016; 9(8): 796. CrossRef - BMP9 inhibits the growth and migration of lung adenocarcinoma A549 cells in a bone marrow stromal cell-derived microenvironment through the MAPK/ERK and NF-κB pathways
JING WANG, YAGUANG WENG, MINGHAO ZHANG, YA LI, MENGTIAN FAN, YANGLIU GUO, YANTING SUN, WANG LI, QIONG SHI
Oncology Reports.2016; 36(1): 410. CrossRef - Comparative proteomic analysis of fibrosarcoma and skin fibroblast cell lines
Ogunc Meral, Hamdi Uysal
Tumor Biology.2015; 36(2): 561. CrossRef - Involvement of Wnt/β-catenin signaling in the mesenchymal stem cells promote metastatic growth and chemoresistance of cholangiocarcinoma
Weiwei Wang, Wei Zhong, Jiahui Yuan, Congcong Yan, Shaoping Hu, Yinping Tong, Yubin Mao, Tianhui Hu, Bing Zhang, Gang Song
Oncotarget.2015; 6(39): 42276. CrossRef
- Transition between canonical to non-canonical Wnt signaling during interactions between mesenchymal stem cells and osteosarcomas
- Relationship between Vimentin Expression and Progression of Uterine Cervix Epithelial Neoplasms.
- Sung Chul Lim, Keun Hong Kee, Hyun Jong Park
- Korean J Pathol. 1998;32(9):663-669.
- 1,727 View
- 10 Download
-
Abstract
- Vimentin is an intermediate filament protein normally expressed in mesenchymal cells, but the evidence of the aberrant expression of vimentin in epithelial cancer cells suggests that the vimentin expression might be related to local invasiveness and metastatic potential. There have been a few previous studies on the vimentin expression in human cervical carcinogenesis using in vivo and in vitro models. We examined the immunohistochemical vimentin expression in various squamous epithelial neoplasms of the uterine cervix, including the cervical intraepithelial neoplasia group (n=25), the microinvasive squamous cell carcinoma group (n=15), the invasive squamous cell carcinoma group (n=15) and the metastatic squamous cell carcinoma group (n=8). Vimentin positivity was significantly higher in the invasive than in the intraepithelial group, and in the cases with lymph node metastasis than in those without metastasis, suggesting a relationship between the vimentin expression and progression of the uterine cervical epithelial tumors.
- Expression of CD44v6 Protein in the Progression of Colorectal Carcinomas.
- Eunhee Lee, Kyoung Mee Kim, Anhi Lee, Byung Kee Kim
- Korean J Pathol. 2000;34(9):636-641.
- 1,895 View
- 15 Download
-
Abstract
PDF
- During tumor progression, a subset of cells acquires metastatic properties, presumably through a series of genetic alterations. CD44 variant glycoproteins containing sequences encoded by exon v6 are related to tumor progression of human colorectal cancer. But their expression in normal colonic epithelium is controversial and studies of CD44 on each step of colorectal carcinogenesis are scanty. We studied CD44v6 expression in the normal colonic mucosa, adenoma, carcinoma in situ, and invasive colorectal carcinomas of different Astler-Coller stages. Endoscopically or surgically resected 36 normal colonic mucosa, 19 adenomas, 8 cases of carcinoma in situ, and 25 cases of carcinoma were selected. After immunohistochemical stain with CD44v6 antibody, positivity was graded as 0 to 4 based on the estimated percentage of positively stained tumor cells. The intensity of positive staining cells was also graded as 0 to 3. In all but one cases (97.2%), normal colorectal mucosa was negative for CD44v6. Positive rates in adenoma, carcinoma in situ, Astler-Coller stage A/B and C/D carcinoma were 73.6%, 88.9% and 87.5%, respectively. There was no statistically significant difference in the positivity between these groups. The staining intensity was significantly higher in the cases of stage C/D carcinoma group than those of adenomas (p<0.05). The percentage of positivity for CD44v6 was higher in stage C/D carcinoma group than adenoma, carcinoma in situ, and stage A/B carcinoma group (p<0.05). Expression of CD44v6 in the normal colonic mucosa was extremely rare and the positivity was increased according to the progression of colorectal tumors. Furthermore, it is more important to interpret the CD44v6 positivity according to the estimated percentage of positively stained tumor cells.
First
Prev
